LONDON – Virax Biolabs Group Limited (NASDAQ: VRAX), a biotech firm specializing in viral disease diagnostics, has extended its exclusive distribution partnership with Cosmos Health Inc. (NASDAQ: COSM) to market its Mpox Virus Real-Time PCR Detection Kits in the Gulf Cooperation Council (GCC) territories. This agreement builds upon Virax’s existing distribution rights in Greece, Cyprus, and non-exclusive rights across Europe.
The PCR detection kits, which have received CE marking for European sales and authorization by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), boast a sensitivity of 96.7% and specificity of 93.72%. Results from the kits are available in under 70 minutes, providing a swift tool for healthcare professionals in the management of the Mpox virus.
James Foster, CEO of Virax Biolabs, expressed enthusiasm about the expanded reach provided by the agreement with Cosmos, highlighting the importance of accessible diagnostic tools in containing infectious diseases. Cosmos CEO Greg Siokas echoed this sentiment, noting the sustained demand for Mpox virus detection and the company’s readiness to support Virax in serving the GCC region.
The enhanced agreement authorizes Cosmos to import, sell, and distribute Virax-branded Mpox virus Nucleic Acid Detection Kits in GCC member states, including Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates.
Virax Biolabs is known for developing T-Cell-based test technologies aimed at providing an immunology profiling platform, which can be crucial in diagnosing and treating post-viral syndromes and immune dysregulation conditions.
Cosmos Health, a diversified healthcare group, has a portfolio that spans pharmaceuticals, nutraceuticals, and a presence in telehealth services. The company’s expansion efforts are supported by its manufacturing capabilities, certified by European Good Manufacturing Practices, and a global distribution network.
This partnership extension is expected to enhance the availability of critical diagnostic solutions in the GCC, contributing to the broader efforts to monitor and manage the spread of the Mpox virus.
The information is based on a press release statement from Virax Biolabs.
In other recent news, Cosmos Health Inc. has achieved several significant milestones. The healthcare group has expanded its distribution of mpox virus detection kits to the Gulf Cooperation Council countries, in partnership with Virax Biolabs. This move is particularly…
Click Here to Read the Full Original Article at All News…
